701 related articles for article (PubMed ID: 12640446)
1. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.
Nicoll JA; Wilkinson D; Holmes C; Steart P; Markham H; Weller RO
Nat Med; 2003 Apr; 9(4):448-52. PubMed ID: 12640446
[TBL] [Abstract][Full Text] [Related]
2. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
[TBL] [Abstract][Full Text] [Related]
3. Abeta species removal after abeta42 immunization.
Nicoll JA; Barton E; Boche D; Neal JW; Ferrer I; Thompson P; Vlachouli C; Wilkinson D; Bayer A; Games D; Seubert P; Schenk D; Holmes C
J Neuropathol Exp Neurol; 2006 Nov; 65(11):1040-8. PubMed ID: 17086100
[TBL] [Abstract][Full Text] [Related]
4. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.
Masliah E; Hansen L; Adame A; Crews L; Bard F; Lee C; Seubert P; Games D; Kirby L; Schenk D
Neurology; 2005 Jan; 64(1):129-31. PubMed ID: 15642916
[TBL] [Abstract][Full Text] [Related]
5. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
Boche D; Denham N; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.
Güntert A; Döbeli H; Bohrmann B
Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022
[TBL] [Abstract][Full Text] [Related]
7. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia.
Bombois S; Maurage CA; Gompel M; Deramecourt V; Mackowiak-Cordoliani MA; Black RS; Lavielle R; Delacourte A; Pasquier F
Arch Neurol; 2007 Apr; 64(4):583-7. PubMed ID: 17420322
[TBL] [Abstract][Full Text] [Related]
8. Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide.
Lue LF; Walker DG
J Neurosci Res; 2002 Nov; 70(4):599-610. PubMed ID: 12404514
[TBL] [Abstract][Full Text] [Related]
9. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease.
Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897
[TBL] [Abstract][Full Text] [Related]
10. HLA-DR alleles in amyloid beta-peptide autoimmunity: a highly immunogenic role for the DRB1*1501 allele.
Zota V; Nemirovsky A; Baron R; Fisher Y; Selkoe DJ; Altmann DM; Weiner HL; Monsonego A
J Immunol; 2009 Sep; 183(5):3522-30. PubMed ID: 19675171
[TBL] [Abstract][Full Text] [Related]
11. Anti-Abeta: The good, the bad, and the unforeseen.
Broytman O; Malter JS
J Neurosci Res; 2004 Feb; 75(3):301-6. PubMed ID: 14743443
[TBL] [Abstract][Full Text] [Related]
12. Immunization of Alzheimer model mice with adenovirus vectors encoding amyloid beta-protein and GM-CSF reduces amyloid load in the brain.
Kim HD; Kong FK; Cao Y; Lewis TL; Kim H; Tang DC; Fukuchi K
Neurosci Lett; 2004 Nov; 370(2-3):218-23. PubMed ID: 15488326
[TBL] [Abstract][Full Text] [Related]
13. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
[TBL] [Abstract][Full Text] [Related]
14. Regression stage senile plaques in the natural course of Alzheimer's disease.
Oide T; Kinoshita T; Arima K
Neuropathol Appl Neurobiol; 2006 Oct; 32(5):539-56. PubMed ID: 16972888
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Alzheimer's disease.
McGeer PL; McGeer E
Sci Aging Knowledge Environ; 2004 Jul; 2004(27):pe29. PubMed ID: 15243154
[TBL] [Abstract][Full Text] [Related]
16. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies.
Lee M; Bard F; Johnson-Wood K; Lee C; Hu K; Griffith SG; Black RS; Schenk D; Seubert P
Ann Neurol; 2005 Sep; 58(3):430-5. PubMed ID: 16130106
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
18. Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model.
Okura Y; Kohyama K; Park IK; Matsumoto Y
J Neuropathol Exp Neurol; 2008 Nov; 67(11):1063-71. PubMed ID: 18957895
[TBL] [Abstract][Full Text] [Related]
19. Lessons from the AN 1792 Alzheimer vaccine: lest we forget.
Robinson SR; Bishop GM; Lee HG; Münch G
Neurobiol Aging; 2004; 25(5):609-15. PubMed ID: 15172738
[TBL] [Abstract][Full Text] [Related]
20. Progranulin expression correlates with dense-core amyloid plaque burden in Alzheimer disease mouse models.
Pereson S; Wils H; Kleinberger G; McGowan E; Vandewoestyne M; Van Broeck B; Joris G; Cuijt I; Deforce D; Hutton M; Van Broeckhoven C; Kumar-Singh S
J Pathol; 2009 Oct; 219(2):173-81. PubMed ID: 19557827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
